drugset / Trial / NCT05134662
ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALT-801 and its effects on glucose control in overweight and obese subjects with type 2 diabetes mellitus (T2DM).
Timeline
- Start
- 2022-02-01
- Primary completion
- 2023-02-03
- Completion
- 2023-03-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALT-801 | Protein / enzyme biologic | 1.2 mg | Subcutaneous |
| Subject | ALT-801 | Protein / enzyme biologic | 1.8 mg | Subcutaneous |
| Subject | ALT-801 | Protein / enzyme biologic | 2.4 mg | Subcutaneous |